Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin

Cellular Oncology

Volumn 37, Issue 6, 2014, Pages 421-428

  Szwed, Marzena ^a   Kania, Katarzyna D ^b   Jozwiak, Zofia ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b INSTITUTE OF MEDICAL BIOLOGY   (Poland)

Author keywords

Doxorubicin; Drug carriers; Multidrug resistance; P glycoprotein; Transferrin

Indexed keywords

ABCB1 PROTEIN, HUMAN; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; TRANSFERRIN;

APOPTOSIS; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; LEUKEMIA; METABOLISM; MULTIDRUG RESISTANCE; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA; P-GLYCOPROTEIN; P-GLYCOPROTEINS; TRANSFERRIN;

EID: 84914685257     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-014-0205-5     Document Type: Article

References (36)

1. B. Ríhová, J. Strohalm, O. Hovorka, V. Subr, T. Etrych, P. Chytil, R. Pola, D. Plocová, J. Boucek, K. Ulbrich, Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences. J. Control. Release 127, 110–120 (2008)
2. M. Mazevet, M. Moulin, A. Llach-Martinez, C. Chargari, E. Deutsch, A.M. Gomez, E. Morel, Complications of chemotherapy, a basic science update. Presse Med. 42, e352–e361 (2013)
3. K.J. Patel, O. Trédan, I.F. Tannock, Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother. Pharmacol. 72, 127–138 (2013)
4. C. Mamot, R. Ritschard, A. Wicki, G. Stehle, T. Dieterle, L. Bubendorf, C. Hilker, S. Deuster, R. Herrmann, C. Rochlitz, Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol. 13, 1234–1241 (2012)
5. B. Ky, P. Vejpongsa, E.T. Yeh, T. Force, J.J. Moslehi, Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ. Res. 113, 754–764 (2013)
6. P.S. Guerreiro, A.S. Fernandes, J.G. Costa, M. Castro, J.P. Miranda, N.G. Oliveira, Differential effects of methoxyamine on doxorubicin cytotoxicity and genotoxicity in MDA-MB-231 human breast cancer cells. Mut Res. 757, 140–147 (2013)
7. S. Aroui, S. Brahim, M.D. Waard, A. Kenani, Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study. Biochem Biophys Res Comm. 391, 419–425 (2010)
8. C.Y. Quan, C. Chang, H. Wei, C.S. Chen, X.D. Xu, S.X. Cheng, X.Z. Zhang, R.X. Zhuo, Dual targeting of a thermo sensitive nanogel conjugated with transferrin and RGD-containing peptide for effective cell uptake and drug release. Nanotechnology 20, 335101 (2009)
9. F. Kratz, Acid-sensitive prodrugs of doxorubicin. Top. Curr. Chem. 283, 73–97 (2008)
10. L.W. Seymour, Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst. 9, 135–187 (1992)
11. F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, R.K. Jain, Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752–3756 (1995)
12. F. Kratz, U. Beyer, T. Roth, N. Tarasova, P. Collery, F. Lechenault, A. Cazabat, P. Schumacher, C. Unger, U. Falken, Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. J. Pharm. Sci. 87, 338–346 (1998)
13. H.C. Arora, M.P. Jensen, Y. Yuan, A. Wu, S. Vogt, T. Paunesku, G.E. Woloschak, Nanocarriers enhance doxorubicin uptake in drug-resistant ovarian cancer cells. Cancer Res. 72, 769–778 (2012)
14. A. Saneja, V. Khare, N. Alam, R.D. Dubey, P.N. Gupta, Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance. Expert Opin Drug Deliv. 11, 121–138 (2014)
15. A.A. Kovalev, D.A. Tsvetaeva, T.V. Grudinskaja, Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp. Oncol. 35, 287–290 (2013)
16. B. Bauer, A.M. Hartz, G. Fricker, D.S. Miller, Modulation of p-glycoprotein transport function at the blood–brain barrier. Exp Biol Med. 230, 118–127 (2005)
17. B. LZ, The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol. Pharm. 6, 1631–1643 (2009)
18. C. Bosquillon, Drug transporters in the lung-implication in the biopharmaceutics of inhaled drugs. J. Pharm. Sci. 99, 2240–2255 (2009)
19. S. Endter, U. Becker, N. Daum, H. Huwer, C.M. Lehr, M. Gumbleton, C. Ehrhardt, P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers. Cell Tissue Res. 328, 77–84 (2007)
20. F.J. Sharom, Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function. Front Oncol (2014). doi:10.3389/fonc.2014.00041
21. A. Berczi, M. Ruthner, V. Szuts, M. Fritzer, E. Schweizner, H. Goldenberg, Influence of conjugation of doxorubicin to transferrin on the iron uptake by K562 cells via receptor-mediated endocytosis. Eur J Bioch. 213, 427–436 (1993)
22. M. Szwed, A. Matusiak, A. Laroche-Clary, J. Robert, I. Marszalek, Z. Jozwiak, Transferrin as a drug carrier: cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells. Toxicol In Vitro. 28, 187–197 (2014)
23. T. Ikegawa, F. Ushigome, N. Koyabu, S. Morimoto, Y. Shoyama, M. Naito, T. Tsuruo, H. Ohtani, Y. Sawada, Inhibition of P-glycoprotein by orange juice components, polymethoxy flavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett. 160, 21–28 (2000)
24. Y. Zhou, M.M. Gottesman, I. Pastan, The extracellular loop between TM5 and TM6 of P-glycoprotein is required for reactivity with monoclonal antibody UIC2. Arch. Biochem. Biophys. 1, 74–80 (1999)
25. R. Gondko, A. Zgirski, M. Adamska, Biostatistics in tasks, 3rd edn. (University of Lodz, Lodz, 2011), pp. 135–141
26. G. Lehne, D.R. Sørensen, G.E. Tjønnfjord, C. Beiske, T.A. Hagve, H.E. Rugstad, O.P. Clausen, The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice. Leukemia 16, 2388–2394 (2002)
27. M.R. Grey, R. Burgess, A. Fisher, J.A. Yin, Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia. Leuk. Res. 23, 29–35 (1999)
28. S. Lo, B. Tolner, J.W. Taanman, J.M. Cooper, M. Gu, J.A. Hartley, A.H. Schapira, D. Hochhauser, Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents. Int. J. Oncol. 27, 337–344 (2005)
29. P.S. Lai, C.L. Pai, C.L. Peng, M.J. Shieh, K. Berg, P.J. Lou, Enhanced cytotoxicity of saporin by polyamidoamine dendrimer conjugation and photochemical internalization. J Biomed Mater Res. A 87, 147–155 (2008)
30. M.J. Shieh, C.L. Peng, P.J. Lou, C.H. Chiu, T.Y. Tsai, C.Y. Hsu, C.Y. Yeh, P.S. Lai, Nontoxic photo-triggered gene transfection by PAMAM–porphyrin conjugates. J. Drug Target. 15, 279–284 (2007)
31. J.J. Yu, H.A. Lee, J.H. Kim, W.H. Kong, Y. Kim, Z.Y. Cui, K.G. Park, W.S. Kim, H.G. Lee, S.W. Seo, Bio-distribution and anti-tumor efficacy of PEG/PLA nanoparticles loaded doxorubicin. J. Drug Target. 15, 279–284 (2007)
32. J.C. Wang, B. Goh, W.L. Lu, Q. Zhang, A. Chang, X.Y. Liu, T.M. Tan, H. Lee, In vitro cytotoxicity of stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol. Pharm. Bull. 28, 822–828 (2005)
33. H.L. Wong, R. Bendayan, A.M. Rauth, X.Y. Wu, Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci. 93, 1993–2008 (2004)
34. J. Wu, Y. Lu, A. Lee, X. Pan, X. Yang, X. Zhao, R.J. Lee, Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 10, 350–357 (2007)
35. C. Mamot, D.C. Drummond, K. Hong, D.B. Kirpotin, J.W. Park, Liposome-based approaches to overcome anticancer drug resistance. Drug Resis Updates. 6, 271–279 (2003)
36. K. Zhang, W. Chen, T. Bu, H. Qi, R. Sun, X. He, Decreased P-glycoprotein is associated with the inhibitory effects of static magnetic fields and cisplatin on K562 cells. Bioelectromagnetics 35, 437–443 (2014)